MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company DPO Ratio 2011-2026 | BMY
Annual DPO Ratio Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94 | 89.6 | 108 | 108 | 104 | 80 | 110 | 105 | 135 | 123 | 146 | 231 | 202 | 174 | 170 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 231 | 80 | 132 |
Quarterly DPO Ratio Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 128 | 112 | 111 | 102 | 98.8 | 107 | 99.4 | 111 | - | 50.3 | 49.4 | 109 | - | 126 | 122 | 91.3 | - | 99 | 91.7 | 64.3 | - | 125 | 113 | 108 | - | 105 | 106 | 119 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 128 | 49.4 | 102 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Verastem
VSTM
|
1.26 K | $ 5.04 | -4.73 % | $ 349 M |  USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arena Pharmaceuticals
ARNA
|
142 | - | -6.81 % | $ 3.04 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
182 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
62.3 | - | - | $ 789 M | USA |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
35.1 | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Xenetic Biosciences
XBIO
|
1.84 K | $ 2.72 | -2.86 % | $ 4.63 M | USA |
 |
XBiotech
XBIT
|
1.26 K | $ 2.27 | -1.73 % | $ 69.2 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
40.5 | $ 54.48 | -1.89 % | $ 4.24 B | Canada |
 |
Xeris Pharmaceuticals
XERS
|
23 | $ 5.4 | -3.05 % | $ 866 M | USA |
 |
X4 Pharmaceuticals
XFOR
|
454 | $ 4.04 | -6.26 % | $ 171 M | USA |
 |
XOMA Corporation
XOMA
|
9.87 K | $ 30.17 | -1.18 % | $ 364 M | USA |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
22nd Century Group
XXII
|
60.9 | $ 2.41 | -18.03 % | $ 444 K | USA |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
Zai Lab Limited
ZLAB
|
232 | $ 18.0 | 2.8 % | $ 19.7 B | China |
|
Enlivex Therapeutics Ltd.
ENLV
|
193 | $ 1.05 | -3.67 % | $ 21.5 M | Israel |